TomoTherapy, the developer of a versatile radiation system used for the treatment of a variety of cancers, announced the terms of its IPO Monday. The company plans to offer 10.9 million shares, including 738 thousand from selling shareholders, at an estimated price range of $15 to $17. Merrill Lynch and Piper Jaffray are the lead underwriters on the deal.
